Free Trial

Alvotech (ALVO) Competitors

Alvotech logo
$9.19 +0.26 (+2.91%)
As of 07/3/2025 02:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ALVO vs. ASND, VTRS, QGEN, MRNA, BPMC, VRNA, BBIO, ROIV, RVMD, and ELAN

Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

Alvotech vs. Its Competitors

Alvotech (NASDAQ:ALVO) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Alvotech has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.98M5.63-$231.86M$0.3724.84
Ascendis Pharma A/S$393.54M27.04-$409.12M-$6.28-27.72

In the previous week, Alvotech had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 8 mentions for Alvotech and 6 mentions for Ascendis Pharma A/S. Alvotech's average media sentiment score of 0.97 beat Ascendis Pharma A/S's score of 0.47 indicating that Alvotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascendis Pharma A/S
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alvotech has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

Alvotech presently has a consensus target price of $18.00, indicating a potential upside of 95.87%. Ascendis Pharma A/S has a consensus target price of $220.67, indicating a potential upside of 26.77%. Given Alvotech's higher probable upside, equities analysts plainly believe Alvotech is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ascendis Pharma A/S
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alvotech has a net margin of 16.42% compared to Ascendis Pharma A/S's net margin of -93.22%. Ascendis Pharma A/S's return on equity of 0.00% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech16.42% -36.37% 12.70%
Ascendis Pharma A/S -93.22%N/A -33.29%

Summary

Alvotech beats Ascendis Pharma A/S on 9 of the 13 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVO vs. The Competition

MetricAlvotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.77B$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E Ratio24.8421.5627.6520.23
Price / Sales5.63283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book-6.717.538.035.65
Net Income-$231.86M-$55.14M$3.18B$249.15M
7 Day Performance0.55%4.61%2.93%3.28%
1 Month Performance-13.79%0.90%1.72%3.95%
1 Year Performance-24.17%5.40%34.39%20.98%

Alvotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVO
Alvotech
3.7357 of 5 stars
$9.19
+2.9%
$18.00
+95.9%
-24.2%$2.77B$491.98M24.841,032
ASND
Ascendis Pharma A/S
3.4754 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+28.2%$10.81B$393.54M-27.991,017News Coverage
Analyst Forecast
VTRS
Viatris
2.6648 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-10.4%$10.41B$14.33B-2.7932,000
QGEN
Qiagen
3.9176 of 5 stars
$46.72
-0.1%
$47.74
+2.2%
+21.0%$10.39B$1.98B117.145,765Dividend Announcement
MRNA
Moderna
4.461 of 5 stars
$25.67
-0.9%
$46.61
+81.6%
-74.2%$10.02B$3.24B-2.945,800Options Volume
Gap Up
BPMC
Blueprint Medicines
1.5514 of 5 stars
$128.40
+0.2%
$128.06
-0.3%
+14.8%$8.28B$508.82M-51.98640High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
2.7827 of 5 stars
$97.05
+2.9%
$101.10
+4.2%
+466.0%$8.03B$42.28M-48.5330News Coverage
Positive News
Analyst Forecast
BBIO
BridgeBio Pharma
4.685 of 5 stars
$42.17
+1.1%
$56.67
+34.4%
+69.7%$7.92B$221.90M-11.95400News Coverage
Insider Trade
Analyst Revision
ROIV
Roivant Sciences
1.5178 of 5 stars
$11.50
+0.4%
$17.50
+52.2%
+1.8%$7.78B$29.05M-46.00860
RVMD
Revolution Medicines
4.5745 of 5 stars
$40.04
+1.0%
$67.08
+67.5%
-1.4%$7.39B$11.58M-10.01250Analyst Revision
ELAN
Elanco Animal Health
2.3907 of 5 stars
$13.36
-0.7%
$15.17
+13.5%
+2.9%$6.68B$4.44B18.059,000News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ALVO) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners